Testing 8M2D Safety in Healthy Adults and Alzheimer's Patients
Part of Brain & nervous system, Mental health clinical trials.
This early-stage trial tests how safe and well-tolerated a new drug called 8M2D is in healthy volunteers and people with early Alzheimer's disease. Researchers want to understand how the body handles the drug and whether it might help slow memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to stay in a clinic for the full treatment period and come back for follow-up visits
- You cannot be pregnant or breastfeeding, and must use contraception if you could become pregnant
- You must have normal heart, kidney, and liver function based on screening tests
- You cannot have smoked or used nicotine in the past 3 months
- You cannot have hepatitis B, hepatitis C, or HIV
- You must not have participated in another drug trial in the past 90 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
Hear when a new Alzheimer's Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.